Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Outcomes research in glomerulonephritis.

Daniel C Cattran1

  • 1University of Toronto, Department of Medicine, Toronto General Hospital, University Health Network, Ontario, Canada. daniel.cattran@uhn.on.ca

Seminars in Nephrology
|August 19, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A secondary analysis of the TESTING trial predicted individual patient response to corticosteroid treatment in IgA nephropathy.

Kidney international·2026
Same author

Long-term Outcome of Adult Patients With Membranous Nephropathy Treated With Rituximab.

Kidney international reports·2025
Same author

Erratum to "Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts" [<i>Kidney International Reports</i> Volume 10, Issue 4, April 2025, Pages 1283-1287].

Kidney international reports·2025
Same author

Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts.

Kidney international reports·2025
Same author

Predicting Remission in Antiphospholipase A2 Receptor Antibody-Associated Membranous Nephropathy: A Secondary Analysis of the GEMRITUX, MENTOR, and STARMEN Trials.

Clinical journal of the American Society of Nephrology : CJASN·2025
Same author

Application of the updated International IgA Nephropathy Prediction Tool in children one or two years post-biopsy.

Kidney international·2024

Glomerulonephritis, a leading cause of kidney failure, requires effective immunotherapy. This review examines treatments for membranous nephropathy, focal segmental glomerulosclerosis, and IgA nephropathy to guide clinical management.

Area of Science:

  • Nephrology
  • Immunology
  • Renal Medicine

Background:

  • Glomerulonephritis is a major cause of end-stage renal failure.
  • Early intervention is crucial for preserving kidney function and quality of life.
  • High incidence in youth underscores the need for effective therapies.

Purpose of the Study:

  • To review immunotherapy outcomes for common glomerulonephritis variants.
  • To provide an evidence-based framework for clinical management.
  • To analyze recent studies on membranous nephropathy, FSGS, and IgA nephropathy.

Main Methods:

  • Systematic review of outcome studies from the past decade.
  • Focus on immunotherapy for progressive glomerulonephritis.
  • Analysis of treatment efficacy and clinical management strategies.

Related Experiment Videos

Main Results:

  • Identified key immunotherapy approaches for specific glomerulonephritis types.
  • Evaluated the strengths and weaknesses of current treatment options.
  • Highlighted the impact of immunotherapy on disease progression and patient outcomes.

Conclusions:

  • Immunotherapy plays a vital role in managing progressive glomerulonephritis.
  • Evidence-based strategies are essential for optimizing patient care.
  • Further research can refine treatment protocols for better renal outcomes.